​

Axsome Therapeutics (AXSM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AXSM Stock Forecast

Axsome Therapeutics (AXSM) stock forecast, based on 26 Wall Street analysts, predicts a 12-month average price target of $282.53, with a high of $380.00 and a low of $246.00. This represents a 34.14% increase from the last price of $210.63.

$50 $120 $190 $260 $330 $400 High: $380 Avg: $282.53 Low: $246 Last Closed Price: $210.63

AXSM Stock Rating

Axsome Therapeutics stock's rating consensus is Buy, based on 26 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 25 Buy (96.15%), 1 Hold (3.85%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 26 1 25 Strong Sell Sell Hold Buy Strong Buy

AXSM Price Target Upside V Benchmarks

TypeNameUpside
StockAxsome Therapeutics34.14%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1851
Avg Price Target$316.00$284.63$243.84
Last Closing Price$210.63$210.63$210.63
Upside/Downside50.03%35.13%15.77%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 263171--21
Aug, 263171--21
Jul, 263171--21
Jun, 263171--21
May, 263171--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 12, 2026Graig SuvannavejhMizuho Securities$316.00$215.7746.45%50.03%
Aug 11, 2026Leonid TimashevRBC Capital$297.00$219.0035.62%41.01%
Aug 11, 2026Morgan Stanley$251.00$221.2113.47%19.17%
Aug 11, 2026Ami FadiaNeedham$268.00$220.8921.33%27.24%
Aug 11, 2026Guggenheim$275.00$220.8924.50%30.56%
Aug 11, 2026Wells Fargo$256.00$220.8915.89%21.54%
Jul 20, 2026Malcolm HoffmanBMO Capital$310.00$221.6439.87%47.18%
Jul 07, 2026Leonid TimashevRBC Capital$304.00$242.6025.31%44.33%
Jun 11, 2026Andrew TsaiJefferies$380.00$246.3454.26%80.41%
May 05, 2026David HoangDeutsche Bank$280.00$230.1021.69%32.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 24, 2026UBSBuyBuyhold
Aug 11, 2026RBC CapitalOutperformOutperformhold
Aug 11, 2026NeedhamBuyBuyhold
Aug 11, 2026GuggenheimBuyBuyhold
Aug 11, 2026UBSBuyPerforminitialise
Aug 11, 2026Wells FargoOverweightOverweighthold
Jul 20, 2026BMO CapitalOutperforminitialise
Jul 07, 2026RBC CapitalOutperformOutperformhold
Jun 17, 2026Cowen & Co.BuyBuyhold
Jun 11, 2026Morgan StanleyReduceOverweightupgrade

Financial Forecast

EPS Forecast

$-10 $-4 $2 $8 $14 $20 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.60$-5.27$-5.99$-3.68---
Avg Forecast$-4.33$-4.26$-5.46$-1.86$3.49$8.94$14.40
High Forecast$-3.58$-4.09$-4.84$1.33$7.55$15.48$18.28
Low Forecast$-5.22$-4.59$-6.42$-6.84$-1.77$1.68$11.37
Surprise %6.24%23.71%9.71%97.85%---

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.04M$270.60M$385.69M$638.50M---
Avg Forecast$46.98M$268.30M$384.09M$632.39M$1.02B$1.47B$2.00B
High Forecast$54.34M$269.66M$387.81M$761.98M$1.03B$1.47B$2.41B
Low Forecast$40.70M$265.55M$380.46M$529.02M$1.02B$1.47B$1.67B
Surprise %6.51%0.86%0.42%0.97%---

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-187.13M$-239.24M$-287.22M$-183.17M---
Avg Forecast$-196.81M$-197.28M$-255.63M$-117.53M$130.33M$454.59M$654.27M
High Forecast$-162.61M$-186.00M$-219.63M$60.27M$342.78M$703.18M$830.30M
Low Forecast$-236.92M$-208.57M$-291.63M$-310.79M$-80.59M$76.31M$516.45M
Surprise %-4.92%21.27%12.36%55.86%---

AXSM Forecast FAQ

Is Axsome Therapeutics stock a buy?

Axsome Therapeutics stock has a consensus rating of Buy, based on 26 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 25 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Axsome Therapeutics is a favorable investment for most analysts.

What is Axsome Therapeutics's price target?

Axsome Therapeutics's price target, set by 26 Wall Street analysts, averages $282.53 over the next 12 months. The price target range spans from $246 at the low end to $380 at the high end, suggesting a potential 34.14% change from the previous closing price of $210.63.

How does Axsome Therapeutics stock forecast compare to its benchmarks?

Axsome Therapeutics's stock forecast shows a 34.14% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Axsome Therapeutics over the past three months?

  • September 2026: 14.29% Strong Buy, 80.95% Buy, 4.76% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 14.29% Strong Buy, 80.95% Buy, 4.76% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 14.29% Strong Buy, 80.95% Buy, 4.76% Hold, 0% Sell, 0% Strong Sell.

What is Axsome Therapeutics’s EPS forecast?

Axsome Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $3.49, marking a -194.84% decrease from the reported $-3.68 in 2025. Estimates for the following years are $8.94 in 2027, and $14.4 in 2028.

What is Axsome Therapeutics’s revenue forecast?

Axsome Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $1.02B, reflecting a 60.05% increase from the reported $638.5M in 2025. The forecast for 2027 is $1.47B, and $2B for 2028.

What is Axsome Therapeutics’s net income forecast?

Axsome Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $130.33M, representing a -171.15% decrease from the reported $-183M in 2025. Projections indicate $454.59M in 2027, and $654.27M in 2028.